Clinical Trials Directory

Trials / Completed

CompletedNCT06767982

Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)

A Randomized Prospective Trial Comparing Bacillus Calmette-Guerin (BCG) RIVM and Russian Strains in Non-Muscle Invasive Bladder Cancer: Efficacy and Side Effects

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
160 (actual)
Sponsor
Ankara University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to compare the efficacy and safety of two Bacillus Calmette-Guérin (BCG) substrains (RIVM and Russian) in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) in adult patients. The main questions it aims to answer are: * Is there a significant difference in recurrence-free survival (RFS) between the BCG RIVM and BCG Russian substrains? * Is there a significant difference in progression-free survival (PFS) between the two substrains? * Are there notable differences in the incidence of treatment-related adverse events between the strains? Researchers will compare patients treated with BCG RIVM to patients treated with BCG Russian to determine whether one substrain offers superior clinical outcomes in terms of recurrence, progression, and adverse events. Participants will: Undergo transurethral resection of bladder tumor (TURBT) prior to initiating therapy. Be randomly assigned to receive either BCG RIVM or BCG Russian intravesical therapy. Receive an induction course of six weekly instillations of the assigned BCG substrain. Receive maintenance therapy at regular intervals (3, 6, 12, 18, 24, 30, and 36 months) based on risk classification. Undergo regular follow-up with cystoscopy and urine cytology to assess recurrence, progression, and adverse events.

Conditions

Interventions

TypeNameDescription
DRUGBacillus Calmette-Guerin (BCG)In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients

Timeline

Start date
2019-01-01
Primary completion
2022-12-31
Completion
2022-12-31
First posted
2025-01-10
Last updated
2025-01-10

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06767982. Inclusion in this directory is not an endorsement.